Microcurrent Stimulation to Treat Macular Degeneration
An Observational, Multi-Center Phase 1 Study of the Safety and Effectiveness of Frequency Specific Microcurrent Stimulation as an Alternative Treatment for Retinal Diseases
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Hawaii
-
Hilo, Hawaii, United States, 96720
- Hawaii Cataract Laser Institute - Hilo
-
Honolulu, Hawaii, United States, 96815
- Retina Institute of Hawaii
-
Kahului, Hawaii, United States, 96732
- Hawaii Cataract Laser Institute - Maui
-
Kailua-Kona, Hawaii, United States, 96740
- Hawaii Cataract Laser Institute - Kona
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Ability to provide written consent and comply with follow up visits
- Age 40 years or older
- ETDRS best corrected visual acuity better than 5 letters
- History of Dry Age Relted Macular Degeneration; Retinitis Pigmentosa; Stargardt's disease
- No Anti-VEGF treatments for at least 3 months prior to study
- No new antioxidant/vitamin supplementation for at least 3 months prior to study
Exclusion Criteria:
- History of Non-Compliance with regular medical visits
- Significant media opacities (exclude NS 4+) that may interfere with assessing visual acuity
- Presence of pigment epithelial tears or rips
- Known serious allergies to fluorescein dye
- Presence of retinal neovascularization
- Any treatment with an investigation agent in the past 30 days
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measure visual acuity after receiving microcurrent stimulation treatments.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: George Papastergiou, MD, Retina Institute of Hawaii
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RIH 1009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Diseases
-
NCT07177196Active, not recruiting
-
NCT03691168RecruitingInherited Retinal Dystrophies
-
NCT01454466CompletedRetinal Detachment | Retinal Break
-
NCT03613948CompletedInherited Retinal Dystrophy Primarily Involving Sensory Retina | Inherited Retinal Dystrophy Primarily Involving Retinal Pigment Epithelium
-
NCT03662386Terminated
-
NCT06212297Active, not recruitingInherited Retinal Dystrophy
-
NCT06177977Recruiting
-
NCT05858983RecruitingBiallelic RPE65 Mutation-associated Retinal Dystrophy
-
NCT05902962CompletedRetinal Dystrophy | PRPF31 Mutationassociated Retinal Dystrophy | RP11
-
NCT04690062UnknownDystrophy, Retinal